AU2020253054B2 - FGFR tyrosine kinase inhibitors for the treatment of urothelial carcinoma - Google Patents

FGFR tyrosine kinase inhibitors for the treatment of urothelial carcinoma

Info

Publication number
AU2020253054B2
AU2020253054B2 AU2020253054A AU2020253054A AU2020253054B2 AU 2020253054 B2 AU2020253054 B2 AU 2020253054B2 AU 2020253054 A AU2020253054 A AU 2020253054A AU 2020253054 A AU2020253054 A AU 2020253054A AU 2020253054 B2 AU2020253054 B2 AU 2020253054B2
Authority
AU
Australia
Prior art keywords
erdafitinib
fgfr3
dose
administration
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020253054A
Other languages
English (en)
Other versions
AU2020253054A1 (en
Inventor
Peter Marie Z. De Porre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of AU2020253054A1 publication Critical patent/AU2020253054A1/en
Application granted granted Critical
Publication of AU2020253054B2 publication Critical patent/AU2020253054B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2020253054A 2019-03-29 2020-03-27 FGFR tyrosine kinase inhibitors for the treatment of urothelial carcinoma Active AU2020253054B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19166429 2019-03-29
EP19166429.1 2019-03-29
US201962833395P 2019-04-12 2019-04-12
US62/833,395 2019-04-12
PCT/EP2020/058814 WO2020201138A1 (en) 2019-03-29 2020-03-27 Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma

Publications (2)

Publication Number Publication Date
AU2020253054A1 AU2020253054A1 (en) 2021-09-30
AU2020253054B2 true AU2020253054B2 (en) 2026-01-08

Family

ID=69954076

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020253054A Active AU2020253054B2 (en) 2019-03-29 2020-03-27 FGFR tyrosine kinase inhibitors for the treatment of urothelial carcinoma

Country Status (15)

Country Link
US (1) US20220175768A1 (https=)
EP (2) EP4548935A3 (https=)
JP (2) JP2022527482A (https=)
KR (1) KR20210143878A (https=)
CN (1) CN113645975A (https=)
AU (1) AU2020253054B2 (https=)
BR (1) BR112021019203A2 (https=)
CA (1) CA3130773A1 (https=)
IL (1) IL286727A (https=)
JO (1) JOP20210260A1 (https=)
MA (1) MA55486A (https=)
MX (1) MX2021011943A (https=)
PH (1) PH12021552352A1 (https=)
SG (1) SG11202109854RA (https=)
WO (1) WO2020201138A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023002980A (es) * 2020-09-14 2023-06-06 Janssen Pharmaceutica Nv Terapias de combinación de inhibidores del fgfr.
KR20240019293A (ko) * 2021-06-07 2024-02-14 알.피.쉐러 테크놀러지즈 엘엘씨 습기 감응성 약학 조성물용 보호 코팅
EP4415692A1 (en) 2021-10-12 2024-08-21 TARIS Biomedical LLC Erdafitinib formulations and systems for intravesical administration
CN119072311A (zh) 2022-02-18 2024-12-03 塔里斯生物医药公司 用于膀胱内施用的厄达替尼制剂和渗透系统
CN116106240B (zh) * 2022-12-26 2025-11-07 华中农业大学 一种尿液酪氨酸检测体系、检测方法及检测试剂盒
CN120731076A (zh) 2023-02-13 2025-09-30 塔里斯生物医药公司 膀胱内施用厄达替尼以用于治疗膀胱癌
JP2026506041A (ja) 2023-02-17 2026-02-20 タリス バイオメディカル エルエルシー 膀胱がんの治療における使用のための膀胱内投与のためのエルダフィチニブ

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
WO1998004689A1 (en) 1995-07-31 1998-02-05 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
MX2007014782A (es) 2005-05-23 2008-02-19 Novartis Ag Formas cristalinas y otras formas de las sales de acido lactico de 4-amino-5-fluoro-3-[6-(4-metilpiperazin-1-il)-1h-bencimidazol-2 -il]-1h quinolin-2-ona.
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
EP4063516A1 (en) 2014-09-26 2022-09-28 Janssen Pharmaceutica NV Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor
AU2018216969B2 (en) * 2017-02-06 2024-04-11 Janssen Pharmaceutica Nv Cancer treatment
MA47408B1 (fr) * 2017-12-20 2023-08-31 Janssen Pharmaceutica Nv Traitement du cancer

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Change, C-H, et al., 'Anticancer Benefits of Early Versus Late Use of Rapamycin in a Rat Model of Urothelial Carcinomal, Transplant Proc., 2014, vol. 46, no. 4, pages 1240 - 1242 *
Hanna, K, 'Updates and novel treatments in urothelial carcinoma', J Oncol Pharm Pract., vol. 25, no. 3, pages 648 - 656 *
Hu, X-P, et al., 'Rapamycin instead of mycophenolate mofetil or azathioprine in treatment of post-renal transplantation urothelial carcinoma', Chin Med J (Engl)., vol. 122, no. 1, pages 35-38 *
Luan, FL, et al., 'Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy', Transplantation, 2002, vol. 73, no. 10, pages 1565 - 1572 *
Poh, A, 'Erdafitinib Efficacious in Bladder Cancer', Cancer Discov., vol. 8, no. 8, pages 1 - 5 *
Soria, J-C, et al., 'Safety and activity of the pan-fibroblast growth factor receptor (FGFR) inhibitor erdafitinib in phase 1 study patients with advanced urothelial carcinoma', vol. 27, vi269 *
Tabernero, J, et al., 'Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors', J Clin Oncol., vol. 33, no. 30, pages 3401 - 3408 *

Also Published As

Publication number Publication date
KR20210143878A (ko) 2021-11-29
PH12021552352A1 (en) 2022-09-05
JP2026048748A (ja) 2026-03-17
EP4548935A2 (en) 2025-05-07
EP3946340A1 (en) 2022-02-09
MA55486A (fr) 2022-02-09
BR112021019203A2 (pt) 2021-11-30
SG11202109854RA (en) 2021-10-28
WO2020201138A1 (en) 2020-10-08
MX2021011943A (es) 2021-11-03
CA3130773A1 (en) 2020-10-08
JOP20210260A1 (ar) 2023-01-30
IL286727A (en) 2021-10-31
CN113645975A (zh) 2021-11-12
EP4548935A3 (en) 2025-08-06
AU2020253054A1 (en) 2021-09-30
US20220175768A1 (en) 2022-06-09
JP2022527482A (ja) 2022-06-02

Similar Documents

Publication Publication Date Title
AU2020253054B2 (en) FGFR tyrosine kinase inhibitors for the treatment of urothelial carcinoma
US20230110113A1 (en) Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer
JP2025156297A (ja) 尿路上皮癌の治療のためのｆｇｆｒチロシンキナーゼ阻害剤
US20250000858A1 (en) Fgfr tyrosine kinase inhibitors for the treatment of advanced solid tumors
HK40126446A (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
HK40064232A (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma
EA052400B1 (ru) Ингибиторы тирозинкиназ fgfr для лечения уротелиальной карциномы
KR20250148646A (ko) 고위험 비근침윤성 방광암 치료를 위한 fgfr 티로신 키나제 억제제
HK40064235A (en) Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma